Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes but it lacks context. This company can't be looked at using a standard fundamental analysis, which is all this is....it's basically useless for a company like Advaxis.
What could Zacks auto generated analysis understand that no one else in the market does?
The negative sentiments are due to the situation the company is in? This is based on basic facts and reality. Whether you like to hear or it or not, no one can argue the company isn't in a very tenuous position with many LTSH facing a reasonable probability of getting wiped out for good.
Regarding Zacks - aren't most their articles just auto generated and there's no "human" analyst behind the rating? Many of their ratings/articles mean next to nothing when you look deeper into it.. imo.
You said you added yesterday and so I assumed you had an opinion on what would happen in the short term. Not that anyone truly knows, but to throw more money in at this point you have to believe something. GL
Ok - what do you think is the likelihood of a r/s then followed by dilution given their cash position and increased burn? I know your all about anything is possible, but what does it look like to you? 50/50?
They have to find a deal or this company wont last. They can't dilute their way to relevance. They are spread too thin, too many drugs, too little cash, no MC, no respect. Advaxis is in the dog house and won't get out till they can prove desire for the platform.
I don't see how a 30 million market cap company (r/s or not) could even raise 100 million? That's >3x their current market cap, how is this possible without major news...
Yes, blue I’m same as you,I’ve already been through the first split but didn’t have enough in to care. I bought again after neo though only to watch it tank and tried my best to average down. I’m done though, I can’t support this company anymore. I’m holding till it ends, I’m wiped out, or they finally follow through on securing a deal. I have zero faith in them anymore given the facts on the ground so I’ve basically accepted the entire loss.
Wow, so we'd lose another 6-7 million in market cap.
They need a deal. If they don't get a deal then I'm wiped out. The r/s and everything else means little, imo.
If the total Aim2Cerv market opportunity is only 400 million, as is mentioned in their corporate slide deck, how much could Advaxis possibly get in upfront cash if they were to sign a deal?
I can't believe it would be that much... Plus it would have to be for both Europe and US together.
Bottom line is, as Huang noted on the call, the world needs more computing power and Nvidia delivers this in spades. As a plus, the world will specifically need more parallel computing power from their GPU's due to general [CPU] computing not being able to keep up their pace of innovation - Moore's law is dead.
If this drops back down to $125 - $140 range, i'll be loading up.
I'm sure he's really upset losing less than a million $ in a multi-billion dollar fund. He couldn't care less.
This is silly. He'll come back if he sees a reason to and ADXS rights the ship.
Yes. I would probably put my estimates on the low end.
These cancer trials can be much more complex/costly than others...
I was purely talking about additional trial costs. 20 sites. 50 patients. $25k - $50k per person?
I really don't know. But it IS an addition cost burden for ADXS that currently doesn't have sufficient funds to even run a year at the current (increasing) cash burn.
I did not say or "imply" anything of the sort related to ADXS's chances of partnering with Merck, iggy. I was replying to CATT's post about there only being 2 trials mentioned, when in fact there were 3.
Was this even meant for me?
I dont know. Maybe they're not there yet with the PSA trial data (or HOT) to announce something?
It does show how many options they do have though and we're just 1 of them.
Merck is initiating three new pivotal prostate cancer trials: KEYLYNK-010 (Keytruda + Lynparza), KEYNOTE-921 (Keytruda + docetaxel and prednisone) and KEYNOTE-621 (Keytruda + Xtandi)
Huh? If you have gains. Are you assuming that no one made money in the market over the last decade of this bull run?
The losses also carryover...
Agree. Only the people that sold are currently on the right side of this bet. Nothing here screams buy until they figure out their INSANE position of trying to fund all these trials without a single partner.
I will say that risk/reward here is Ok though, these are basically call options at this point...
Don't forget we're also paying for a HOT trial now as well. No more reimbursements for expenses related to NEO either from Amgen. These guys are taking this down to the last minute.
If you were down 90%+ and used it as a tax write-off it's hardly a dumb move. Writing off your big loss is a better return than the doubling from the bottom it did recently. Plus you have no clue where this goes, there may be another lower low depending on what happens with the split and raise, and they can all get back in now whenever they want....
Shouldn’t the cash burn be accelerating now that neo is no longer covered and HoT is now in trial, with additional constructs moving forward?
Now that the early NEO data was not good enough for Amgen to continue to support the tech
I partially agree with this. They no doubt saw the data that ADXS just presented at the IO 360 conference and still pulled the plug. But we DO NOT know if that positive data, while somewhat expected, will amount to an any kind of actual tumor response as it's too early to tell.
ADXS is adding a PD1, which is basically acknowledging NEO and HOT are nothing special compared to the zillion other competing treatments in development
This is ridiculous. So what if they add a PD1 to the treatment? This doesn't mean much of anything to me and is probably the smart thing to do, there is no shame in giving the drug its best chance to succeed by combining it with a PD1.
Also, not sure what "zillion" other competing treatments you speak of...
Yep. The problem for me was chasing this down. Had I just left my initial investment in this, as I had planned, I wouldn't care all that much. I tried to average down, and so far that was STUPID. This stock has only gotten worse and worse with countless poor decisions and let downs. Now I might get wiped out totally. Lesson learned
Hope for an AH announcement for NEO. I keep dreaming...
Yes - I voted no as well, out of principle. And we have every right to after everything that has happened. We all know they'll get their shares in the end.
Bottom line is a partnership WITH cash is the only thing that will fix this, regardless of the r/s or share ask. We'll be destroyed if they dont find one because they need cash right now. Such a sad state of affairs. Spread so thin.
This has been the case for a couple years now. Still waiting.
NEO spending will accelerate our cash burn until we find a partner. They have to prove NOW that the science can be partnered or else...
Imo,the company would do a 1 for 10,and that`s why they asked for 75 mln insulated
That's still 750 mln shares pre-split.
If they don’t strike a deal soon we’ll all be slaughtered, that’s just the reality of it. They have no cash and burn far too much for a company at this market cap, NEO as of last week is now on OUR dime.
I don’t have any more money to throw at these guys.. nor would I want to.
Yes, but was also down 30 plus percent the day prior when they announced it would happen...
Not to be subject to the r/s so yes, it could be a lot more than 75 million on a post r/s amount
Thank you for this. HOV tried to explain reality, but no one will listen. Just show me A partnership and they can call it first class all they want.
This felt like they were fishing for a partner at this thing more than anything else. Whether it was for HOT, NEO, or any of their other products. Time is ticking.
Now that Amgen dumped this first in class product there must be plenty of BP chomping at the bit to take it over. Amgen got this thing to first base on their dime, should be a steal now.
I agree. This does seem like more fluff to me. Nothing new here and I doubt anything new will be said during the actual presentation.
In the end, none of it matters anyways, they need partners and that's the only way this will continue. I hope they have a NEO partner lined up but that seems like a long shot so soon after being dumped.
For NEO? Where did you gather that?
If I were a scientist working for Adxs and read this message board , I would walk to another company that is respectful of my talents . All the scientist could do is short the stock and walk away , make a fortune playing all of you .
First off, most here have already been played and are down 90% plus.
Second, no one is blaming the scientists here. They're blaming the execution and business decisions of the company by its management and bod. They're the ones who have watched this stock get utterly decimated while piling on the negatives including dilutions, r/s, outsized pay, abhorrent fiscal management, poor hiring, failed partnerships, terrible AXAL comments, I mean this list could go on and on.
The science only suffers from this poor execution. 100's of millions spent and here we are with 30 left and our only paying partnership gone. At least the scientists are still getting paid.
They have $30mm cash on hand while burning $50mm/year and will have no paying partners as of this month, what do you think the price should be?
I admit that when Amgen was still a partner for NEO I thought this stock was well underpriced, even after they pulled the EMA app and thought of shelving AXAL, now idk.
2 decades in business, 100's of millions spent, ample amounts of data and ZERO partners. They can sign a deal with BP any day now to prove their products are "ground breaking"
Something is not right with this company, other than management.
So now management is in cahoots with Amgen to tank the share price in order to help them acquire a 70% ownership stake? That's a new one.
Also, it's insane.
Amgen could buy Advaxis today for a fraction of their cash on hand. Shareholders would approve a relatively modest price of 1 billion right now. In your "hypothetical" I'm with Amgen that 3-4 billion is a crazy number. Not to mention Advaxis has no ground to stand on, they're dead broke.
Also, there was no reason for them to cancel it and say what they said if all they were going to do is renegotiate the deal. They could have just renegotiated the terms and moved forward. This fantasy just sounds great from a drama perspective, nothing more.
Rev: $1.42bln vs $1.45 estimate. EPS: $.08 vs $.08 estimate. Stock is up in AH.
The big takeaway is the doubling of EPYC unit sales to datacenters and the ramp up of 7nm coming mid 2019. This should be a huge boon for AMD if they can continue this growth, especially in the $20+ billion datacenter market with their new 7nm ROME CPU launching soon.
Also to note is their new wafer amendment with Glofo: "The amendment provides AMD full flexibility for wafer purchases from any foundry at the 7nm node and beyond without any one-time payments or royalties." This will allow them to maintain their manufacturing advantage without any substantial penalty going forward..
Last earnings report also had them revise down on guidance and lower revenues. The crypto bust was a big issue for them back then. I believe some of that should be balanced out now.